Incidence and Risk Factors of Oral Mucositis in Patients with Breast Cancer Who Receiving Chemotherapy in Al-Bashir Hospital

  • Ahmed A. Al Ibraheemi Clinical Oncology Resident Doctor, Clinical Oncology and Radiation Therapy Department, Al-Bashir Hospital, Al-Ashrafiyah, Amman, Jordan
  • Shaimaa Shamoun Oncology Nurse Specialist, Clinical Oncology and Radiation Therapy Department, Al-Bashir Hospital, Al-Ashrafiyah, Amman, Jordan
Risk factors, Oral mucositis, Breast cancer, Taxane


Background: Oral Mucositis (OM) remains the most common side effect of chemotherapy affects negatively on patients' quality of life.

Subjects and Methods: Convenience samples of patients who received chemotherapy were followed from first or second cycle of chemotherapy until OM occurrence. We reviewed 75 female patients with breast cancer who received chemotherapy with mean age (47.2 SD ± 8.62861). We used WHO scale to assess the severity of OM. Demographic and other variables (age, number of cycle before appearance of signs of OM, WBC count, neutropenia count, creatinine and BMI) were filled in questionnaire.

Results: 81.3% of reviewed patients were suffering from OM and (52.4%) of them were shown score 2 according to WHO classification, Taxane included chemotherapy protocol was the only significant variable that associated with OM occurrence (p=0.009).

Conclusion: In this study; Taxane is the only risk factor that significantly associated with occurrence of OM.


Sonis ST. Oral mucositis in cancer therapy . J Support Oncol. 2004; 2(6 suppl 3):3-8.

Stokman MA, Sonis ST, Dijkstra PU, et al. Assessment of oral mucositis in clinical trials: impact of training on evaluators in a multi-centertrial. Eur J Cancer. 2005; 41(12):1735-8.

Cheng KK. Oral Mucositis and quality of life of Hong Kong Chinese Patients with cancer therapy. Eur J Oncol Nurs. 2007; 11(1):36-42.

Cheng KK, Leung SF, Liang RH, et al. A patient-reported outcome instrument to assess the impact of oropharyngealmucositis onhealth-related quality of life: a longitudinal psychometric evaluation. Support Care Cancer. 2009; 17(4),389-98.

Bhatt V, Vendrell N, Nau K, et al. Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation. J Oncol Pharm Pract. 2010; 16(3):195–204.

Sung L, Tomlinson GA, Greenberg ML, et al. Validation of the oral mucositis assessment scale in pediatric cancer. Pediatr Blood Cancer. 2007; 49 (2):149-153.

Karagözoğlu S, Filiz Ulusoy M. Chemotherapy: the effect of oral cryotherapyon Thedevelopment of mucositis. J Clin Nurs. 2005; 14(6):754-65.

Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in Cancer patients: unanswered questions. Oral Oncol. 2003; 39(2):91-100.

Köstler WJ, Hejna M, Wenzel C, et al. Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA Cancer J Clin. 2001; 51(5): 290–315.

Dodd MJ, Miaskowski C, Dibble SL, et al. Factors influencing oral mucositis in patients receiving chemotherapy. Cancer Pract. 2000; 8(6):291-7.

Otmani N, Alami R, Soulaymani A, et al. Sex, age and ABO blood groups in chemotherapy-induced oropharyngeal mucositis. Minerva Stomatol. 2008; 57(10):505-9.

Chen HM. Patients experiences and perceptions of Chemotherapy-Induced oral mucositisin a day unit. Cancer Nurs. 2008; 31(5):363-9.

Suresh AV, Varma PP, Sinha S, et al. Risk-scoring system for predicting mucositis in patients of head and neck cancerreceiving concurrent chemoradiotherapy [rssm-hn]. J Cancer Res Ther. 2010; 6(4):448-51.

Wilkes JD. Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol. 1998; 25(5):538-51.

Pico JL, Avila-Garavito A, Naccache P. Mucositis: Its Occurrence, Consequences, and Treatment in the Oncology Setting. Oncologist. 1998; 3(6):446-51.

Borowski B, Benhamou E, Pico JL, et al. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomized controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol. 1994; 30B(2):93-7.

Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy induced mucosal injury. Cancer. 2004; 100(9 Suppl):1995-2025.

Raber-Durlacher JE, Weijl NI, Abu Saris M, et al. Oral mucositis in patients treated with chemotherapy for solid tumors 2012: aretrospective analysis of 150 cases. Support Care Cancer. 2000; 8(5):366-71.

Vokurka S, Steinerova K, Karas M, et al. Characteristics and riskfactors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL Conditioning regimen in context with BU/CY2. Bone Marrow Transplant. 2009; 44(9):601–5.

Saito N, Imai Y, Muto T, et al. Low body mass index as a risk factor of moderate to severe oral mucositis in oral cancerpatients with diotherapy. Support Care Cancer. 2012; 20(12): 3373-7.

How to Cite
Al Ibraheemi AA, Shamoun S. Incidence and Risk Factors of Oral Mucositis in Patients with Breast Cancer Who Receiving Chemotherapy in Al-Bashir Hospital. Int J Hematol Oncol Stem Cell Res. 10(4):217-223.